Key Highlights

● Compass reported third-quarter results on November 9.

● It ended the period with $163 million in cash.

● The cash provides a runway into 2028.

● It is pursuing a BLA despite an FDA request.

Results with a long runway

Compass Therapeutics (NASDAQ:CMPX) drew attention on Monday, November 9, 2026, after the clinical-stage biotech reported third-quarter results. According to news reports, the company's net loss widened from a year earlier, but it ended the period with $163 million in cash, which it said provides a runway into 2028.

Market data reported that Compass is continuing to pursue a Biologics License Application, or BLA, despite a request from the US Food and Drug Administration. The details of that request were not spelled out in the report, but the company's decision to keep moving forward put its regulatory strategy front and center.

Why cash runway is a big deal

For a biotech company without meaningful product revenue, cash runway is one of the most important numbers on the balance sheet. It tells investors how long the Business can fund research, trials and regulatory work before it may need to raise more money. Raising Capital can dilute existing shareholders, especially if it happens when a stock is under pressure.

A runway extending into 2028 gives Compass time to work through its regulatory process without an immediate need to tap markets. A widening net loss is common for companies in this phase, as spending tends to rise when programs advance toward approval.

What a BLA means

A Biologics License Application is the formal request a company submits to the FDA to market a biological product, such as an antibody, in the United States. Compass develops antibody-based treatments for cancer, and a BLA would mark a step from clinical development toward potential commercialization.

FDA requests during the run-up to or review of an application can involve additional data, analyses or other information. How a company responds can influence both timing and the eventual outcome, which is why investors pay close attention to any communication between a drugmaker and the agency.

A busy day for biotech

Compass's update came on a day packed with clinical and regulatory news. Vir Biotechnology (NASDAQ:VIR) jumped after a Phase 3 hepatitis Delta trial met its main goal, while Zura Bio (NASDAQ:ZURA) collapsed after a hidradenitis suppurativa study missed its primary endpoint. NovoCure (NASDAQ:NVCR) received an FDA not-approvable letter for its Optune Mya application, according to market coverage, a reminder of how regulatory decisions can shape a company's path.

The broader market was in a buying mood. The Russell 2000 surged 86.71 points to 2,840.81, its best session since March 31, and the S&P 500 rose 173.08 points to 7,549.94. Falling oil prices, driven by hopes for a US-Iran peace deal, and a rebound in chip stocks lifted shares across sectors.

Regulatory Path Takes Priority

The key items for Compass are regulatory. Investors will be watching for updates on how the company addresses the FDA's request and on the timing of its BLA. Any additional data releases from its cancer programs could also influence sentiment.

The company's cash position will remain in view as well, particularly how quickly spending rises as it moves toward a potential approval. More broadly, Tuesday's October Consumer Price Index and the Federal Reserve's December 8-9 meeting, where a rate hike is widely expected, could affect the funding climate for clinical-stage biotech companies that may eventually need to raise capital.